A Study of LY2922083 in Healthy Participants and Participants With Diabetes

Phase 1

Completed

Brief Summary: The aim of this trial is to evaluate the safety of the study drug in healthy participants and participants with diabetes. It will investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.

The study consists of two parts. Part A will study healthy participants in up to 3 dosing periods over approximately 6 weeks. Part B will study participants with diabetes in up to 3 dosing periods over approximately 6 weeks.

Recruitment & Eligibility

Inclusion Criteria

For all participants :

Must be a male, or a female who cannot become pregnant, and who is either a healthy participant, or who has type 2 diabetes
Have a screening body mass index (BMI) of at least 18.0 kilograms per square meter (kg/m^2)
Have blood pressure, pulse rate, blood and urine laboratory test results acceptable for the study

For participants with T2DM:

Do not have any change to their diabetes treatment (exercise with or without metformin) for at least 4 weeks prior to screening
Have a glycated hemoglobin (HbA1c) value of greater than or equal to 6% and less than or equal to 11% at screening

Exclusion Criteria

For all participants :

Are currently participating in another clinical study or completed one in the last 30 days
Are allergic to LY2922083 or other related drugs
Have a history of significant heart, lung, liver, kidney, stomach or brain disease, or have any medical problems which may cause an increased risk during the study
Have electrocardiogram (ECG) readings that are not suitable for the study
Have a history of hepatitis or jaundice
Are infected with hepatitis B
Are infected with hepatitis C
Are infected with human immunodeficiency virus (HIV)
Have donated more than 450 milliliters (mL) of blood in the last 3 months or have donated any blood in the last month
Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week (female), or are unwilling to stop alcohol as required by the study restrictions (1 unit = 360 mL of beer, or 150 mL of wine, or 45 mL of spirits)
Smoke more than 10 cigarettes per day or are not willing to abstain from smoking while at the clinic

For participants with T2DM :

Have had heart disease or stroke within 6 months before entering the study
Have health complications due to poorly controlled diabetes as shown by blood and urine laboratory test results or based on physical examination and medical assessment as determined by the study doctor
Have been hospitalized for poor control of diabetes (keto-acidotic episode) in the last 6 months
Have used insulin to control diabetes in the last 1 year
Show symptoms of high blood sugar (for example, frequent urination, always feeling thirsty, or unexpected weight loss)

Arm && Interventions

Group	Intervention	Description
Placebo (Part A)	Placebo	Single oral dose of placebo administered to healthy participants in up to 1 of 3 study periods in Part A
LY2922083 (Part A)	LY2922083	Single ascending dose of LY2922083 (starting at 0.5 milligrams \[mg\]) administered orally to healthy participants in up to 2 of 3 study periods in Part A
Placebo (Part B)	Placebo	Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B
LY2922083 (Part B)	LY2922083	Single ascending dose of LY2922083 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A

Primary Outcome Measures

Name	Time	Method
Number of Participants With 1 or More Serious Adverse Event(s) (SAEs)	Baseline through study completion (up to 70 days)	Events deemed by the Investigator to be SAEs related to study drug administration are reported. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics (PK): Area Under the Concentration Curve From Time 0 to Infinite Time [AUC(0-∞)] of LY2922083	Predose up to 72 hours (h) after each dose of study drug (Part A: predose, 0.5, 1.5, 2.5, 4, 6, 12, 18, 24, 36, 48 and 72 h postdose. Part B: predose, 0.5, 1.5, 4, 6, 12, 18, 24, 36, 48 and 72 h postdose.)
PK: Maximum Concentration (Cmax) of LY2922083	Predose up to 72 h after each dose of study drug (Part A: predose, 0.5, 1.5, 2.5, 4, 6, 12, 18, 24, 36, 48 and 72 h postdose. Part B: predose, 0.5, 1.5, 4, 6, 12, 18, 24, 36, 48 and 72 h postdose.)
Change From Baseline in C-Peptide Area Under the Effective Concentration Curve From Time 0 to 6 h Postdose [AUEC(0-6)]	Baseline (predose for Part A and Day -1 time-matched for Part B), up to 6 h postdose (1.5, 2.5, 4, 4.5, 5, and 6 h postdose)	LS mean values were adjusted for baseline, treatment, period, treatment sequence, participant and error.
Change From Baseline in Blood Glucose Area Under the Effective Concentration Curve From Time 0 to 24 h Postdose [AUEC(0-24)]	Baseline (predose for Part A and Day -1 time-matched for Part B), up to 24 h postdose (1.5, 2.5, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18, and 24 h postdose)	Least Squares (LS) mean values were adjusted for baseline, treatment, period, treatment sequence, participant and error.

Locations (1): For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇸🇬
Singapore, Singapore